- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01584362
Single Ascending Dose Safety Study of Oxfendazole (OXFEND-02)
August 29, 2016 updated by: Robert Gilman, Johns Hopkins Bloomberg School of Public Health
Phase I Study of Oxfendazole (Toward the Treatment of Neurocysticercosis)
This research is being done to learn about the safety in humans of a medicine that is already used in cows and pigs to treat worms.
The medicine may be useful for people who have these or other worms.
The medicine will be studied first in healthy people, who will be given a very small amount of the medicine once.
If the smallest amount of medicine is found to be safe, a slightly higher amount will be given to a new group of volunteers.
The highest amount that will be tested is similar to the amount given to animals.
If the medicine can be given safely to healthy people in the planned amounts, a later study will be done in people who have worms to see if the medicine kills the worms.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The Phase I study proposed is a randomized, double-blind, placebo-controlled evaluation of the safety and pharmacokinetics of escalating single oral doses of oxfendazole (0.3 to 30 mg/kg) in healthy volunteers.
The dose will be increased approximately three-fold (one-half log) at each increment, and each cohort will comprise ten volunteers (eight drug, two placebo).
Subjects will be monitored for three weeks after dosing, including monitoring the pharmacokinetics and metabolism of oxfendazole in blood and urine.
Each new cohort will be dosed only after the three week safety data for the preceding group have been analyzed.
If a clinically significant adverse event is observed, and if this event is possibly drug-related, an additional (and final) cohort of volunteers will repeat the highest tolerated dose of oxfendazole.
Up to 70 volunteers (56 drug, 14 placebo) will complete the study.
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Height and weight within 25% of means for his/her gender and age.
- Willing to use two acceptable methods of contraception (approved oral, injectable, or implantable drug, IUD, diaphragm or condom with spermicidal jelly or foam, or sexual abstinence) for a minimum of one week before, and three weeks after dosing with oxfendazole; or surgically sterile.
- Able to give written informed consent.
- Able to provide a home phone number, and the name, address, and phone number of a person willing to assist making contact during the follow-up phase of the study.
Exclusion Criteria:
- Pregnant.
- Breast feeding.
- Chronic drug/alcohol user.
- Has clinically significant abnormalities in screening examinations
- Has history of sensitivity to related benzimidazole compounds (e.g. albendazole, mebendazole).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: oxfendazole 0.3
administration of a single oral 0.3mg/kg dose of oxfendazole
|
administration of a single oral 1.0 mg/kg dose of oxfendazole
administration of a single oral 3.0 mg/kg dose of oxfendazole
administration of a single oral 0.3 mg/kg dose of oxfendazole
administration of a single oral 10 mg/kg dose of oxfendazole
administration of a single oral 20 mg/kg dose of oxfendazole
administration of a single oral 30 mg/kg dose of oxfendazole
|
PLACEBO_COMPARATOR: placebo comparator
administration of a single oral dose of placebo
|
single oral dose of placebo
|
EXPERIMENTAL: oxfendazole 1.0
administration of a single oral 1.0 mg/kg dose of oxfendazole
|
administration of a single oral 1.0 mg/kg dose of oxfendazole
administration of a single oral 3.0 mg/kg dose of oxfendazole
administration of a single oral 0.3 mg/kg dose of oxfendazole
administration of a single oral 10 mg/kg dose of oxfendazole
administration of a single oral 20 mg/kg dose of oxfendazole
administration of a single oral 30 mg/kg dose of oxfendazole
|
EXPERIMENTAL: oxfendazole 3.0
administration of a single oral 3 mg/kg dose of oxfendazole
|
administration of a single oral 1.0 mg/kg dose of oxfendazole
administration of a single oral 3.0 mg/kg dose of oxfendazole
administration of a single oral 0.3 mg/kg dose of oxfendazole
administration of a single oral 10 mg/kg dose of oxfendazole
administration of a single oral 20 mg/kg dose of oxfendazole
administration of a single oral 30 mg/kg dose of oxfendazole
|
EXPERIMENTAL: oxfendazole 10
administration of a single oral 10 mg/kg dose of oxfendazole
|
administration of a single oral 1.0 mg/kg dose of oxfendazole
administration of a single oral 3.0 mg/kg dose of oxfendazole
administration of a single oral 0.3 mg/kg dose of oxfendazole
administration of a single oral 10 mg/kg dose of oxfendazole
administration of a single oral 20 mg/kg dose of oxfendazole
administration of a single oral 30 mg/kg dose of oxfendazole
|
EXPERIMENTAL: oxfendazole 20
administration of a single oral 20 mg/kg dose of oxfendazole
|
administration of a single oral 1.0 mg/kg dose of oxfendazole
administration of a single oral 3.0 mg/kg dose of oxfendazole
administration of a single oral 0.3 mg/kg dose of oxfendazole
administration of a single oral 10 mg/kg dose of oxfendazole
administration of a single oral 20 mg/kg dose of oxfendazole
administration of a single oral 30 mg/kg dose of oxfendazole
|
EXPERIMENTAL: oxfendazole 30
administration of a single oral 30 mg/kg dose of oxfendazole
|
administration of a single oral 1.0 mg/kg dose of oxfendazole
administration of a single oral 3.0 mg/kg dose of oxfendazole
administration of a single oral 0.3 mg/kg dose of oxfendazole
administration of a single oral 10 mg/kg dose of oxfendazole
administration of a single oral 20 mg/kg dose of oxfendazole
administration of a single oral 30 mg/kg dose of oxfendazole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
serious adverse events
Time Frame: up to three weeks after dosing
|
Proportion of patients who present with serious adverse events (SAEs) related to oxfendazole.
|
up to three weeks after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events
Time Frame: up to three weeks after dosing
|
proportion of subjects who present with adverse events (AEs) related to ocfendazole
|
up to three weeks after dosing
|
Pharmacokinetic Profile
Time Frame: blood samples are drawn at 17 time points up to three weeks and urine is collected at 7 intervals up to 72 hours after dosing
|
The following PK parameters will be analyzed: Maximum plasma concentration (Cmax), Time to Cmax (Tmax), Elimination rate constant (Iz), Elimination half-life (T½), Area under the curve to the final sample (AUC0-t), Area under the curve to infinity (AUC∞), Oral clearance (CL/F), Oral volume of distribution (Vz/F) |
blood samples are drawn at 17 time points up to three weeks and urine is collected at 7 intervals up to 72 hours after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Robert H Gilman, MD, Johns Hopkins University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gonzalez AE, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, Romero M, Gilman RH. Treatment of porcine cysticercosis with oxfendazole: a dose-response trial. Vet Rec. 1997 Oct 18;141(16):420-2. doi: 10.1136/vr.141.16.420.
- Gonzales AE, Garcia HH, Gilman RH, Gavidia CM, Tsang VC, Bernal T, Falcon N, Romero M, Lopez-Urbina MT. Effective, single-dose treatment or porcine cysticercosis with oxfendazole. Am J Trop Med Hyg. 1996 Apr;54(4):391-4. doi: 10.4269/ajtmh.1996.54.391.
- Gonzalez AE, Falcon N, Gavidia C, Garcia HH, Tsang VC, Bernal T, Romero M, Gilman RH. Time-response curve of oxfendazole in the treatment of swine cysticercosis. Am J Trop Med Hyg. 1998 Nov;59(5):832-6. doi: 10.4269/ajtmh.1998.59.832.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (ACTUAL)
August 1, 2016
Study Completion (ACTUAL)
August 1, 2016
Study Registration Dates
First Submitted
April 18, 2012
First Submitted That Met QC Criteria
April 24, 2012
First Posted (ESTIMATE)
April 25, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
August 30, 2016
Last Update Submitted That Met QC Criteria
August 29, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Parasitic Diseases
- Helminthiasis
- Cestode Infections
- Central Nervous System Helminthiasis
- Central Nervous System Parasitic Infections
- Cysticercosis
- Taeniasis
- Neurocysticercosis
- Anti-Infective Agents
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Oxfendazole
Other Study ID Numbers
- OXFEND-02, IND 113,628
- IND 113,628 (OTHER: FDA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tenia Solium Infection
-
Institute of Tropical Medicine, BelgiumUniversité Catholique de Louvain; University Ghent; Ministry of Health, Zambia; University of ZambiaCompletedTaenia Solium InfectionZambia
-
All India Institute of Medical Sciences, New DelhiNot yet recruitingNeurocysticercosis | Tenia Solium Infection | Tropical Disease
-
Oregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National University...Completed
-
West Virginia UniversityEnrolling by invitationSkin and Soft Tissue Infection | Gastrointestinal Infection | Pulmonary Infection | Bone and Joint Infection | Endovascular Infection | Genitourinary InfectionUnited States
-
Ondine Biomedical Inc.CompletedSurgical Site Infection | Nosocomial Infection | Healthcare Associated InfectionUnited States
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
Croydon Health Services NHS TrustCompletedSurgical Site Infection | Wound Infection | Cesarean Section; Infection | Perineal InfectionUnited Kingdom
-
Cairo UniversityRecruitingPostoperative Infection | Cesarean Section Complications | Vaginal InfectionEgypt
-
Leiden University Medical CenterRadboud University Medical Center; University Medical Center Groningen; Erasmus... and other collaboratorsRecruitingProsthetic-joint Infection | Infection Hip | Infection; Knee, JointNetherlands
-
University of ZurichCompletedProsthetic Joint Infection | Surgical Site Infection | Prosthesis and Implants | Postoperative Wound Infection Deep Incisional Surgical SiteSwitzerland
Clinical Trials on oxfendazole
-
National Institute of Allergy and Infectious Diseases...CompletedHelminthic InfectionUnited States
-
Swiss Tropical & Public Health InstituteDrugs for Neglected Diseases; Ifakara Health InstituteCompleted
-
Johns Hopkins Bloomberg School of Public HealthUniversidad Peruana Cayetano HerediaWithdrawn
-
National Institute of Allergy and Infectious Diseases...CompletedNeurocysticercosisUnited States
-
Universidad Peruana Cayetano HerediaNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruiting
-
Asociacion Benefica PrismaUniversity of Iowa; National Institutes of Health (NIH); University of Virginia; Policlinico Asociacion Benefica PRISMA-Laboratorio Satelite IQTLABNot yet recruiting
-
Oxfendazole Development GroupUniversidad Peruana Cayetano Heredia, Lima, PeruNot yet recruiting
-
University of ArkansasNational Institutes of Health (NIH); Ortho Biotech Clinical Affairs, L.L.C.Completed